[ Ссылка ] - During the past 10 years, the use of transcatheter aortic valve replacement (TAVR) for treating aortic stenosis has soared from an estimated 4,600 cases in 2012 to over 100,000 cases last year. To learn the latest patient insights about TAVR, we interviewed Dr. G. Michael Deeb, a Professor of Cardiac Surgery and aortic valve specialist at University of Michigan Health.

Key questions addressed by Dr. Deeb include:

1. How has TAVR reduced the physical trauma for aortic valve replacement patients? What should patients know about the differences of TAVR compared to surgical aortic valve replacement (SAVR)?

2. Which patients are candidates for TAVR? What role does patient risk have specific to whether-or-not a patient diagnosed with severe aortic stenosis can get TAVR?

3. What is the latest clinical research specific to TAVR valve deterioration?

4. How has the idea of TAVR durability evolved over the years? What role does hemodynamics and valve gradients play in understanding TAVR or SAVR durability?

5. Why should patients consider going to a multidisciplinary team that performs all types of aortic valve therapy for the lifetime management of aortic valve disease?

To learn more about TAVR and aortic stenosis, please visit [ Ссылка ].

свернуть